KR20240163705A - Shp2 억제제의 결정질 염 형태 - Google Patents

Shp2 억제제의 결정질 염 형태 Download PDF

Info

Publication number
KR20240163705A
KR20240163705A KR1020247034661A KR20247034661A KR20240163705A KR 20240163705 A KR20240163705 A KR 20240163705A KR 1020247034661 A KR1020247034661 A KR 1020247034661A KR 20247034661 A KR20247034661 A KR 20247034661A KR 20240163705 A KR20240163705 A KR 20240163705A
Authority
KR
South Korea
Prior art keywords
cancer
compound
article
ppm
anhydrous form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034661A
Other languages
English (en)
Korean (ko)
Inventor
케이티 키튼 브라운
코너 제임스 카우드리
아론 키스 굿윈
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20240163705A publication Critical patent/KR20240163705A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247034661A 2022-03-23 2023-03-20 Shp2 억제제의 결정질 염 형태 Pending KR20240163705A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23
US63/323,005 2022-03-23
PCT/IB2023/052709 WO2023180898A1 (en) 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor

Publications (1)

Publication Number Publication Date
KR20240163705A true KR20240163705A (ko) 2024-11-19

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034661A Pending KR20240163705A (ko) 2022-03-23 2023-03-20 Shp2 억제제의 결정질 염 형태

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2025509818A (ja) 2025-04-11
TW202346282A (zh) 2023-12-01
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
AR128847A1 (es) 2024-06-19
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
AU2023238523B2 (en) 2025-10-30
AU2023238523A1 (en) 2024-08-22
MX2024011603A (es) 2024-09-30
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
JP6530792B2 (ja) Ｓｙｋ阻害剤
US20240190843A1 (en) Crystalline form of a shp2 inhibitor
WO2021088945A1 (zh) 作为shp2抑制剂的化合物及其应用
CN116096710A (zh) 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
KR102603153B1 (ko) C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도
JP2026506002A (ja) Ｓｏｓ１阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物
CN118791505A (zh) 一种含肟结构的杂环化合物及其制备方法与用途
JP7554007B2 (ja) Ｊａｋ阻害剤化合物及びその使用
EP2531197B1 (en) Solid state forms of macrocyclic kinase inhibitors
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
WO2017162611A1 (en) Quinoline-3-carboxamide compounds and their use in treating cancer
US20250214966A1 (en) Crystalline Salt Form Of A SHP2 Inhibitor
AU2020242723A1 (en) BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN114026088A (zh) Jak2抑制剂的结晶形式
HK40112682A (zh) Shp2抑制剂的结晶盐形式
EP4570800A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
US20250230173A1 (en) Salt forms of an axl inhibitor
US20230192710A1 (en) Jak inhibitor compound and use thereof
CA3263285A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
HK40101911A (zh) Shp2抑制剂的晶型
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof
CN117460725A (zh) Shp2抑制剂的晶型
BR112023019849B1 (pt) 3,4-di-hidro-2,7- naftiridina-1,6(2h,7h)-dionas, composições que os compreendem, usos dos mesmos, e kits
HK40092562B (zh) 用於治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241017

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application